Lifecore Biomedical Inc. (NASDAQ:LFCR) shares closed 33% lower on Monday following the company’s recent fourth-quarter financial results announcement.

Earnings Snapshot

In its latest report, Lifecore announced fourth-quarter revenues of $35.7 million, up 9.8% year over year, almost in line with the consensus of $35.2 million.

Additionally, the company recorded transition period revenues of $75.5 million, reflecting a 20% increase year-over-year.

The company reported a quarterly loss of 16 cents, missing the consensus of 15 cents.

Lifecore 2026 Outlook and Strategy

Lifecore expects 2026 to reflect steady operational execution following a strong 2025 transition year, as it continues positioning for long-term growth.

For 2026, the company guides revenue of $120 million–$125 million versus consensus of $129.85 million, with net loss of $28.9–$32.9 million, and adjusted EBITDA between $20.5–$25 million.

Several customer-specific headwinds temper the 2026 outlook:

Loss of a customer due to a shift in supply strategy.

Temporary demand impact from a customer building excess ...